Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)

Allergan1,099 enrolled

Overview

To investigate the effectiveness of the newer IOP-lowering therapies, as prescribed in normal clinical practice, in larger patient numbers. Patients will be assessed at baseline, at each follow-up visit (follow-up visits are variable as per physician discretion) and at final follow-up visit.

Study Type

OBSERVATIONAL

Enrollment

1,099

Conditions

Open-Angle Glaucoma Ocular Hypertension

Interventions

bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%DRUG

1 drop in eye(s) every evening

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * A diagnosis of Primary Open-Angle Glaucoma or Ocular Hypertension newly diagnosed OR presenting with insufficiently controlled IOP on current medication (in the opinion of the treating physician) * Patient is having both eyes treated Exclusion Criteria: * Contraindications per product labelling will apply. * Patients with any ophthalmic co-morbidity with an influence on visual field deterioration or optic nerve head damage.

Locations (1)

Unnamed facility

Murfreesboro, Tennessee, United States

Outcomes

Primary Outcomes

Change From Baseline in Bilateral Intraocular Pressure (IOP) at One Year

Change from baseline in bilateral (both eyes) IOP at the 1 year follow-up visit. IOP is a measure of the fluid pressure inside the eye. The bilateral IOP was calculated as an average between both eye's IOP. A negative number change from baseline indicates reduction in IOP (improvement).

Time frame: Baseline, 1 Year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.